We confirmed these findings using an additional well-characterized CD133/PROM1HIGH patient-derived GBM cell line, GBM8, which has previously been demonstrated to contain > 90% CD133/PROM1HIGH cells [63, 64]. This evidence concerns the gene PROM1 and glioblastoma.